BACKGROUND: Epileptogenic glioblastomas are thought to convey a favorable prognosis, either due to early diagnosis or potential antitumor effects of antiepileptic drugs. We investigated the relationship between survival and epilepsy at presentation, early diagnosis, and antiepileptic drug therapy in glioblastoma patients. METHODS: Multivariable Cox regression was applied to survival data of 647 consecutive patients diagnosed with de novo glioblastoma between 2005 and 2013 in order to investigate the association between epilepsy and survival in glioblastoma patients. In addition, we quantified the association between survival and valproic acid (VPA) treatment. RESULTS: Epilepsy correlated positively with survival (HR: 0.75 (95% CI: 0.61-0.92), P < .01). This effect is independent of age, sex, performance status, type of surgery, adjuvant therapy, tumor location, and tumor volume, suggesting that this positive correlation cannot be attributed solely to early diagnosis. For patients who presented with epilepsy, the use of the antiepileptic drug VPA did not associate with survival when compared with patients who did not receive VPA treatment. CONCLUSION: Epilepsy is an independent prognostic factor for longer survival in glioblastoma patients. This prognostic effect is not solely explained by early diagnosis, and survival is not associated with VPA treatment.
BACKGROUND: Epileptogenic glioblastomas are thought to convey a favorable prognosis, either due to early diagnosis or potential antitumor effects of antiepileptic drugs. We investigated the relationship between survival and epilepsy at presentation, early diagnosis, and antiepileptic drug therapy in glioblastomapatients. METHODS: Multivariable Cox regression was applied to survival data of 647 consecutive patients diagnosed with de novo glioblastoma between 2005 and 2013 in order to investigate the association between epilepsy and survival in glioblastomapatients. In addition, we quantified the association between survival and valproic acid (VPA) treatment. RESULTS:Epilepsy correlated positively with survival (HR: 0.75 (95% CI: 0.61-0.92), P < .01). This effect is independent of age, sex, performance status, type of surgery, adjuvant therapy, tumor location, and tumor volume, suggesting that this positive correlation cannot be attributed solely to early diagnosis. For patients who presented with epilepsy, the use of the antiepileptic drug VPA did not associate with survival when compared with patients who did not receive VPA treatment. CONCLUSION:Epilepsy is an independent prognostic factor for longer survival in glioblastomapatients. This prognostic effect is not solely explained by early diagnosis, and survival is not associated with VPA treatment.
Authors: M Weller; T Gorlia; J G Cairncross; M J van den Bent; W Mason; K Belanger; A A Brandes; U Bogdahn; D R Macdonald; P Forsyth; A O Rossetti; D Lacombe; R-O Mirimanoff; C J Vecht; R Stupp Journal: Neurology Date: 2011-08-31 Impact factor: 9.910
Authors: Tanya I Yuen; Andrew P Morokoff; Andrew Bjorksten; Giovanna D'Abaco; Lucy Paradiso; Sue Finch; Daniel Wong; Christopher A Reid; Kim L Powell; Kate J Drummond; Mark A Rosenthal; Andrew H Kaye; Terence J O'Brien Journal: Neurology Date: 2012-07-25 Impact factor: 9.910
Authors: Christopher A Barker; Andrew J Bishop; Maria Chang; Kathryn Beal; Timothy A Chan Journal: Int J Radiat Oncol Biol Phys Date: 2013-03-20 Impact factor: 7.038
Authors: Mèlanie S M van Breemen; R M Rijsman; M J B Taphoorn; R Walchenbach; H Zwinkels; Charles J Vecht Journal: J Neurol Date: 2009-05-12 Impact factor: 4.849
Authors: Christian Hartmann; Bettina Hentschel; Matthias Simon; Manfred Westphal; Gabriele Schackert; Jörg C Tonn; Markus Loeffler; Guido Reifenberger; Torsten Pietsch; Andreas von Deimling; Michael Weller Journal: Clin Cancer Res Date: 2013-08-05 Impact factor: 13.801
Authors: Jia-Shu Chen; Ross Clarke; Alexander F Haddad; Elaina J Wang; Michel Lacroix; Indra Neil Sarkar; Ramin Zand; Elizabeth S Chen; Steven A Toms Journal: J Neurooncol Date: 2022-01-04 Impact factor: 4.130
Authors: Varun Venkataramani; Matthias Schneider; Ulrich Herrlinger; Frank Winkler; Frank Anton Giordano; Thomas Kuner; Wolfgang Wick Journal: Nat Rev Cancer Date: 2022-04-29 Impact factor: 69.800
Authors: Kristin M Knudsen-Baas; Anders Engeland; Nils Erik Gilhus; Anette M Storstein; Jone F Owe Journal: J Neurooncol Date: 2016-07-04 Impact factor: 4.130